Articles

Kenyan Growth To Remain Strong In 2024

Country Risk / Kenya / Tue 02 Jan, 2024

Key View

  • We forecast that Kenyan real GDP growth will remain strong at 5.2% in 2024, against estimated growth of 5.5% in 2023 – we have upwardly revised our 2023 estimate from 5.2% previously, following the release of stronger-than-expected Q323 data, while our 2024 forecast represents a downwards revision from our previous projection of 5.4%
Read More

Quick View: Robot-Assisted Lung Biopsies Are A Potential New Revenue Stream For Surgical Robotics Manufacturers

Medical Devices / Global / Tue 02 Jan, 2024

The Latest: Robot-assisted lung biopsies are emerging as a new technology to support earlier lung cancer diagnosis. The robots allow physicians to access more difficult to reach lung nodules than a biopsy performed by a physician, as they are smaller and more minimally invasive. This can support better treatment outcomes for lung cancer, as

Read More

Pakistan’s Current Account Deficit Will Widen In FY2023/24

Country Risk / Pakistan / Tue 02 Jan, 2024

Key View

  • Pakistan’s current account deficit narrowed to just 0.7% of GDP in FY2022/23 (July 2022 to June 2023), but we think that strengthening domestic demand will cause the shortfall to widen to 1.4% in FY2023/24.
  • The recent narrowing of the deficit was due almost entirely to import compression, rather than stronger export earnings. We
Read More

Quick View: AstraZeneca’s Acquisition Of Mainland China’s Biotech Firm Will Enrich Drugmakers Pipeline In Cell Therapies

Pharmaceuticals / China / Tue 02 Jan, 2024

The Latest: On December 26 2023, AstraZeneca announced its plan to make one of its first acquisitions in Mainland China and acquire Gracell Biotechnologies for up to USD1.2bn to increase its investment in cell therapies for treating cancer. The proposed acquisition will add a potential new treatment for multiple myeloma, a type of bone marrow

Read More

Quick View: BMS’s Acquisition Of Karuna Therapeutics Will Support Its Growing CNS Portfolio

Pharmaceuticals / United States / Fri 29 Dec, 2023

The Latest: On December 22 2023, Bristol Myers Squibb (BMS) announced plans to acquire Karuna Therapeutics, a central nervous system (CNS) company that specialises in developing therapeutics for psychiatric and neurological disorders, including schizophrenia and Alzheimer’s disease (AD) psychosis. The deal is worth a total of USD14bn.

Implicatio

Read More
Download Indicator Summary
 

Thank you. Your download link will be emailed to you shortly.

Download Now
 

Thank you. Your download link will be emailed to you shortly.

Download Now
 

Thank you. Your download link will be emailed to you shortly.

Clearbit Form
 

Thank you. Your download link will be emailed to you shortly.